麻豆传媒

Feature Channels: Pharmaceuticals

Filters close
Go to Advanced Search
access_time Embargo lifts in 2 days
This news release is embargoed until 3-Apr-2025 2:00 PM EDT Released to reporters: 2-Apr-2025 7:55 PM EDT

A reporter's PressPass is required to access this story until the embargo expires on 3-Apr-2025 2:00 PM EDT The 麻豆传媒 PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.

Released: 2-Apr-2025 10:50 AM EDT
35-year Industry-Academic Partnership Yielding Groundbreaking Advances for Science and Patients Renews for Another Three Years Between La Jolla Institute for Immunology and Kyowa Kirin
La Jolla Institute for Immunology

Together, the two organizations have created a unique alliance that blends the academic prowess of LJI with the drug development and commercialization expertise of Kyowa Kirin.

麻豆传媒: Mount Sinai Launches AI Small Molecule Drug Discovery Center
Released: 2-Apr-2025 9:00 AM EDT
Mount Sinai Launches AI Small Molecule Drug Discovery Center
Mount Sinai Health System

The Icahn School of Medicine at Mount Sinai has launched the AI Small Molecule Drug Discovery Center, a bold endeavor that harnesses artificial intelligence (AI) to revolutionize drug development. The new Center will integrate AI with traditional drug discovery methods to identify and design new small-molecule therapeutics with unprecedented speed and precision. Unlike conventional drug discovery, which can take years and cost billions, AI-driven approaches enable researchers to rapidly navigate a vast chemical landscape, including natural products, to pinpoint promising drug candidates. By leveraging Mount Sinai鈥檚 world-leading expertise in machine learning, chemical biology, and biomedical data science, the Center aims to bring innovative treatments to patients faster鈥攑articularly for diseases with urgent unmet needs, including cancer, metabolic disorders, and neurodegenerative diseases.

麻豆传媒: Antibiotics Exposure in Infancy May Boost Diabetes Risk
Released: 31-Mar-2025 5:55 PM EDT
Antibiotics Exposure in Infancy May Boost Diabetes Risk
University of Colorado Boulder

Exposure to antibiotics during infancy can stunt the growth of insulin-producing cells in the pancreas and may boost risk of diabetes later in life. The findings shine a light on the importance of the infant microbiome and could lead to new approaches for addressing metabolic diseases.

Released: 31-Mar-2025 5:35 PM EDT
King Charles III Coronation Medal awarded to UdeM members
Universite de Montreal

Recognizing their outstanding contribution to Canada or on the international stage, the medal commemorates the crowning of the former Prince of Wales in 2022.

     
麻豆传媒: Rutgers Health Dean Recognized for Building Strong Community
Released: 27-Mar-2025 7:45 PM EDT
Rutgers Health Dean Recognized for Building Strong Community
Rutgers University-New Brunswick

Joseph A. Barone, dean of Rutgers Ernest Mario School of Pharmacy, was presented with the Bowl of Hygeia Award from the American Pharmacists Association and the New Jersey Pharmacists Association

Released: 27-Mar-2025 7:30 PM EDT
UC San Diego Moores Cancer Center Receives $1M Donation from Pfizer for Early Cancer Detection
University of California San Diego

Moores Cancer Center at the University of California San Diego has received a $1 million donation from pharmaceutical company Pfizer to support an innovative new program designed to bolster early cancer detection and prevention efforts. The donation will help build a bridge bringing research discoveries to community health centers and improving access to early detection tests for colorectal, breast, cervical and prostate cancer.

Released: 27-Mar-2025 10:20 AM EDT
Engenheiros de manufatura da Mayo Clinic est茫o prestes a entregar novas bioterapias
Mayo Clinic

Engenheiros de manufatura est茫o na vanguarda de trazer novos medicamentos derivados de fontes humanas, como c茅lulas, sangue e genes, para os pacientes. Eles produzem o que muitas vezes s茫o bioterapias pioneiras do seu tipo para doen莽as que anteriormente tinham poucas ou nenhuma op莽茫o de tratamento.

   
Released: 27-Mar-2025 9:45 AM EDT
Mayo Clinic Manufacturing Engineers on the Cusp of Delivering New Biotherapies
Mayo Clinic

Manufacturing engineers are at the forefront of bringing new medicines derived from human sources such as cells, blood and genes to patients. They produce what are often first-of-their kind biotherapies for diseases that previously had few or no treatment options.

   
Released: 27-Mar-2025 9:15 AM EDT
Ingenieros de manufactura de Mayo Clinic est谩n a punto de entregar nuevas bioterapias
Mayo Clinic

JACKSONVILLE, Florida 鈥 Ingenieros de manufactura est谩n a la vanguardia de llevar nuevos medicamentos derivados de fuentes humanas, como c茅lulas, sangre y genes, a los pacientes. Ellos producen lo que a menudo son bioterapias pioneras de su tipo para enfermedades que anteriormente ten铆an pocas o ninguna opci贸n de tratamiento.

   
Released: 27-Mar-2025 8:10 AM EDT
CDI Labs Launches Technology Access Program for Custom PhIP-Seq Libraries for Massively Multiplexed Analysis of Serum Antibodies
CDI LABORATORIES, INC.

CDI Labs Canada Inc., a leading provider of services for proteome-wide antibody profiling and target identification, today announced the launch of its Technology Access Program for custom peptide libraries for serum antibody analysis services. These services utilize phage display immunoprecipitation sequencing (PhIP-Seq), a powerful method of multiplexed analysis that combines next-generation proteomics with high-throughput DNA sequencing, to provide researchers with unparalleled insights into the intricate connection between antibodies and diseases.

Released: 27-Mar-2025 12:05 AM EDT
賲賴賳丿爻賵 丕賱鬲氐賳賷毓 賮賷 賲丕賷賵 賰賱賷賳賰 毓賱賶 兀毓鬲丕亘 鬲賯丿賷賲 毓賱丕噩丕鬲 丨賷賵賷丞 噩丿賷丿丞
Mayo Clinic

噩丕賰爻賵賳賮賷賱貙 賵賱丕賷丞 賮賱賵乇賷丿丕 鈥 賷丨鬲賱 賲賴賳丿爻賵 丕賱鬲氐賳賷毓 丕賱氐丿丕乇丞 賮賷 噩賱亘 丕賱兀丿賵賷丞 丕賱噩丿賷丿丞 丕賱賲卮鬲賯丞 賲賳 賲氐丕丿乇 亘卮乇賷丞貙 賲孬賱 丕賱禺賱丕賷丕 賵丕賱丿賲 賵丕賱噩賷賳丕鬲貙 賱賱賲乇囟賶. 賵賷賳鬲噩賵賳 毓賱丕噩丕鬲 丨賷賵賷丞 睾丕賱亘賸丕 賲丕 鬲賰賵賳 丕賱兀賵賱賶 賲賳 賳賵毓賴丕 賱兀賲乇丕囟 賱賲 賷賰賳 賱賴丕 賮賷 丕賱爻丕亘賯 爻賵賶 禺賷丕乇丕鬲 毓賱丕噩賷丞 賲丨丿賵丿丞 兀賵 賱賲 賷賰賳 賱賴丕 兀賷 禺賷丕乇丕鬲.

   
麻豆传媒: tariff-risks-and-opportunities.jpg
Released: 26-Mar-2025 8:20 PM EDT
Risk Matters: Tariff Risks and Opportunities for Pharma Manufacturers
University of Maryland, Robert H. Smith School of Business

Risk management expert Clifford Rossi warns that pharma tariffs could disrupt supply chains, raise costs, and pressure manufacturers, especially generics. Adopting continuous manufacturing offers efficiency gains, balancing risk mitigation with strategic investment.

     
麻豆传媒: A Breakthrough Moment: McMaster Researchers Discover New Class of Antibiotics
Released: 26-Mar-2025 12:00 PM EDT
A Breakthrough Moment: McMaster Researchers Discover New Class of Antibiotics
McMaster University

A McMaster University team led by renowned researcher Gerry Wright has identified a strong candidate to challenge even some of the most drug-resistant bacteria on the planet: a new molecule called lariocidin.

麻豆传媒: A Review of Latest Tools and Technologies in Pharmaceutical Research
Released: 26-Mar-2025 9:35 AM EDT
A Review of Latest Tools and Technologies in Pharmaceutical Research
Chinese Academy of Sciences

This comprehensive review analyzes cutting-edge tools and technologies in modern pharmaceutical research, focusing on artificial intelligence, multi-omics technologies, and experimental methods. The study highlights how computational methods enhance drug discovery efficiency, while omics technologies provide systematic frameworks for investigating drug mechanisms. The integration of these advanced approaches has enabled more diverse and personalized treatment strategies, though challenges remain in drug development complexity, cost-effectiveness, and operational feasibility.

麻豆传媒: Blue Pigment Improves Foundation Makeup Shades for Dark Skin
Released: 26-Mar-2025 5:00 AM EDT
Blue Pigment Improves Foundation Makeup Shades for Dark Skin
American Chemical Society (ACS)

Darker makeup foundations often fall flat, appearing gray-like once applied on the skin. But now, researchers report a blue cosmetic color additive that gives darker foundations the warmth and depth that current formulations lack. They will present their results at ACS Spring 2025.

麻豆传媒: El pigmento azul mejora el tono de las bases de maquillaje para pieles oscuras
Released: 26-Mar-2025 5:00 AM EDT
El pigmento azul mejora el tono de las bases de maquillaje para pieles oscuras
American Chemical Society (ACS)

Las bases de maquillaje m谩s oscuras suelen fallar de plano, ya que dan un aspecto gris谩ceo al aplicarlas sobre la piel. Pero ahora, los investigadores informan de un aditivo de color azul para cosm茅ticos que proporciona a las bases m谩s oscuras la calidez e intensidad de las que carecen las f贸rmulas actuales. Presentar谩n sus resultados en el encuentro de primavera de 2025 de la ACS.

Released: 25-Mar-2025 7:25 PM EDT
Phenomenex Introduces Biozen鈩 Native RP-1 and RP-5: A Novel Way to Characterize ADCs with Unmatched Throughput and High-Quality Data
Phenomenex

Phenomenex Introduces Biozen鈩 Native RP-1 and RP-5: A Novel Way to Characterize ADCs with Unmatched Throughput and High-Quality Data

麻豆传媒: Ibuprofen Inhibits Human Sweet Taste and Glucose Detection by Taste Cells, According to Monell Center Study
Released: 25-Mar-2025 8:55 AM EDT
Ibuprofen Inhibits Human Sweet Taste and Glucose Detection by Taste Cells, According to Monell Center Study
Monell Chemical Senses Center

A team from the Monell Chemical Senses Center and Rutgers University have published a study in the British Journal of Pharmacology that indicates anti-inflammatory medications like ibuprofen and naproxen could be another way to reduce the risk of metabolic diseases by inhibiting the sweet taste receptor throughout the body.

麻豆传媒: Silk Sponges Instead of Animal Testing: How a 3D Cell Culture System Could Revolutionize Cancer Diagnostics
Released: 21-Mar-2025 5:00 AM EDT
Silk Sponges Instead of Animal Testing: How a 3D Cell Culture System Could Revolutionize Cancer Diagnostics
University of Vienna

An FFG-funded consortium of Austrian research groups from the University of Vienna, MedUni Vienna and Technikum Wien together with company partner DOC Medikus GmbH has developed an innovative bioanalytical test system for radiopharmaceutical drug candidates for cancer diagnosis and therapy. It does not require any animal testing at all and enables automated, fast and highly precise analyses. The new method was presented in detail in the renowned Journal of Nuclear Medicine.



close
3.50646